Abstract:Spinal muscular atrophy (SMA) is a congenital neuromuscular disorder characterized by motor neuron loss, resulting in progressive weakness. SMA is notable in the health care community because it accounts for the most common cause of infant death resulting from a genetic defect. SMA is caused by low levels of the survival motor neuron protein (SMN) resulting from SMN1 gene mutations or deletions. However, patients always harbor various copies of SMN2, an almost identical but functionally deficient copy of the gene. A genotype–phenotype correlation suggests that SMN2 is a potent disease modifier for SMA, which also represents the primary target for potential therapies. Increasing comprehension of SMA pathophysiology, including the characterization of SMN1 and SMN2 genes and SMN protein functions, has led to the development of multiple therapeutic approaches. Until the end of 2016, no cure was available for SMA, and management consisted of supportive measures. Two breakthrough SMN-targeted treatments, either using antisense oligonucleotides (ASOs) or virus-mediated gene therapy, have recently been approved. These two novel therapeutics have a common objective: to increase the production of SMN protein in MNs and thereby improve motor function and survival. However, neither therapy currently provides a complete cure. Treating patients with SMA brings new responsibilities and unique dilemmas. As SMA is such a devastating disease, it is reasonable to assume that a unique therapeutic solution may not be sufficient. Current approaches under clinical investigation differ in administration routes, frequency of dosing, intrathecal versus systemic delivery, and mechanisms of action. Besides, emerging clinical trials evaluating the efficacy of either SMN-dependent or SMN-independent approaches are ongoing. This review aims to address the different knowledge gaps between genotype, phenotypes, and potential therapeutics.

Antisense-based Therapy for the Treatment of Spinal Muscular Atrophy

RNA-based drug discovery for spinal muscular atrophy: a story of small molecules and antisense oligonucleotides

Current and emerging targeted therapies for spinal muscular atrophy

Advances and limitations for the treatment of spinal muscular atrophy

Recent Advance in Disease Modifying Therapies for Spinal Muscular Atrophy

An Overview of the Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy

Challenges and opportunities in spinal muscular atrophy therapeutics

Diving into progress: a review on current therapeutic advancements in spinal muscular atrophy

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies

Recent Progress in Gene-Targeting Therapies for Spinal Muscular Atrophy: Promises and Challenges

Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain.

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing

Discovery, synthesis, and biological evaluation of novel SMN protein modulators

Role of circulating biomarkers in spinal muscular atrophy: insights from a new treatment era

Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease

Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy

New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?

Synergistic Effect of an Antisense Oligonucleotide and Small Molecule on Splicing Correction of the Spinal Muscular Atrophy Gene